Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001654954-19-001020
Filing Date
2019-02-05
Accepted
2019-02-05 06:16:27
Documents
1
Period of Report
2019-02-05

Document Format Files

Seq Description Document Type Size
1 US FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION a0843p.htm 6-K 43680
  Complete submission text file 0001654954-19-001020.txt   44805
Mailing Address 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS CAMBRIDGE X0 CB2 0AA
Business Address 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS CAMBRIDGE X0 CB2 0AA 011 44 20 7304 5000
ASTRAZENECA PLC (Filer) CIK: 0000901832 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-11960 | Film No.: 19566136
SIC: 2834 Pharmaceutical Preparations